PMVP

PMV Pharmaceuticals, Inc. is a precision oncology company. The Company is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is deploying its precision oncology platform to target p53 mutations and other p53-related cancers. Its lead product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. In addition to its rezatapopt program, it is focused on developing a pipeline of product candidates targeting other p53 mutations or p53-related targets. These programs have been developed using its precision oncology platform.

Wall Street analysts forecast PMVP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMVP is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

PMV Pharmaceuticals Inc revenue for the last quarter amounts to -22.88M USD, increased 13.43 % YoY.

PMV Pharmaceuticals Inc. EPS for the last quarter amounts to -18313000.00 USD, increased 1043.13 % YoY.

PMV Pharmaceuticals Inc (PMVP) has 63 emplpoyees as of August 13 2025.

Today PMVP has the market capitalization of 75.25M USD.